Aalto Bio Reagents Announces its SARS-CoV-2 Nucleocapsid Protein and...
Updated: May 11
Aalto Bio Reagents announces its Sars nCOV 2 Nucleocapsid protein and Monoclonals to NP are capable of detecting the conserved nucleoprotein Domain of Sars -cov-2 variants of interest including Omicron B.1.1.529.
Dublin, Ireland – December 13th 2021 – Aalto Bio Reagents Ltd. a leading developer of critical raw
materials and reagents for the development of diagnostic tests globally, announced today that its
Sars-CoV-2 n proteins CK6404 and monoclonals CA1360 which are part of numerous rapid assays
being run on the screening frontline in Europe and the U.S., are capable of detecting the conserved
nucleoprotein domain of Sars cov2 variants of interest including Omicron.
From the start of this COVID-19 pandemic in January 2019, Aalto Bio has supported over 50 global
diagnostic companies and vaccine developers with critical raw materials for use in building tests,
enabling frontline testing using multiples of millions of diagnostic tests. In February 2020 Aalto Bio
began offering its first nucleocapsid COVID-19 protein soon after the emergence of the Wuhan strain
of the virus. This was followed in April 2020 by COVID-19 lysis buffer reagent for pre-treating COVID-
19 samples prior to testing, together with monoclonals which were launched in late April. The early
availability of our COVID 19 proteins and Mabs has helped diagnostic manufacturers and vaccine
developers alike build high quality assays with our critical raw materials to faster determine the
clinical status of COVID-19.
“Aalto Bio Reagents Ltd. remain on hand to help our diagnostic manufacturing partners and vaccine
developers around the globe meet their COVID-19 diagnostic testing requirements. As new variants
emerge, we will continue to build critical materials as we have done since the outset of this world
health crisis and deliver first in class critical raw materials. We will continue to offer ourselves to
help innovate diagnostic testing to faster diagnose this virus“, stated Philip Noone CEO Aalto Bio.
About Aalto Bio Reagents
Founded in 1978, Aalto Bio Reagents is a leading developer and provider of raw materials to the in-
vitro diagnostics industry and research laboratories globally. We serve the largest multinational
companies in our industry with a broad range of purified human proteins; monoclonal and
polyclonal antibodies; fungal, parasitic, bacterial and viral antigens; and disease state plasma for in-
vitro diagnostic application.
Since the company's inception, we have built strong working relationships with our clients who trust
us to provide them with the highest quality raw materials to meet the exacting standards of their
own product development requirements. Headquartered in Dublin, Ireland, the company is rapidly
expanding both its product portfolio and customer base. For further information please visit
Contact Aalto Bio Reagents:
Tel: +353-1-4900685 | Email: email@example.com